Discussion
hypogonadism, prostate cancer, high-grade tumors
CVD, HYPOGONADISM, PROSTATE, PROSTATE CANCER, PROSTATE CANCER
The TRAVERSE study is, to our knowledge, the largest randomized trial of TRT conducted to date, with prospectively recorded and adjudicated prostate safety outcomes. Among middle-aged and older men with hypogonadism who had or were at increased risk of CVD, the incidence of high-grade or any prostate cancer in TRT-treated men with a baseline PSA concentration less than 3.0 ng/mL was low and not significantly different from that in placebo-treated men. This group of men whose PSA concentration is less than 3.0 ng/mL represents most of the aging US population.Prostate cancer is highly prevalent among older men, but only a small fraction have high-grade tumors.